Laboratoire de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, AP-HP, Univ Paris-Sud, Le Kremlin Bicêtre, France.
Clin Pharmacol Ther. 2011 Jan;89(1):60-4. doi: 10.1038/clpt.2010.241. Epub 2010 Nov 24.
Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wild-type NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).
口服而非透皮雌激素治疗会增加绝经后女性静脉血栓栓塞（VTE）的风险。ESTHER 研究的数据被用来研究 NFE2L2 rs6721961 基因多态性的影响，该基因多态性可能会损害雌激素代谢物依赖 Nrf2 的肝结合。与非使用者相比，野生型 NFE2L2 患者中口服雌激素的当前使用者的 VTE 比值比（OR）为 2.5（95%置信区间（CI）：1.3-4.8），而该多态性患者的 OR 为 17.9（95%CI：3.7-85.7）（交互作用，P = 0.01）。
Zotero 插件